This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Roche Bid Could Alter Pharma's DNA

The thought of Genentech going away as a separate publicly traded company is very strange to ponder. In many ways, Genentech is the biotech sector, if you get my meaning. Not having that "DNA" ticker symbol around will be very strange -- and sad.

A New M&A Trend?

Will the Roche-Genentech deal spur further merger activity in the biotech sector?

Deals like this can't hurt, and I'd expect some strength in the overall biotech sector as a result, but I'd also be cautious about predicting a broader biotech buyout trend based on Roche-Genentech.

As Roche said repeatedly today, there is an existing relationship between the two companies. Roche already benefits mightily from its 56% stake in Genentech, so now it will benefit even more. There existed a certain inevitability to Roche buying the rest of Genentech.

Will this induce other Big Pharma companies to gobble up the likes of a Biogen Idec (BIIB - Get Report), Gilead Sciences (GILD - Get Report) or Celgene (CELG - Get Report), or go after smaller, more speculative biotech firms?

Perhaps, but it's hard to make a bet on something like that. Such talk has been percolating for years and with a few exceptions, we haven't seen many mega-deals take place.

The way I look at it, Genentech on its own was one of the best, if not the best, biotech investment in the sector. Those investors that agreed and owned the stock are now going to profit. So, buy good biotech companies with strong fundamentals and perhaps you, too, will wake up Monday morning to some happy news.

Lastly, if Roche successfully buys the rest of Genentech, the New York Stock Exchange should retire the DNA ticker symbol permanently. Hang a flag from the rafters of the trading floor to remember the greatest and most successful biotech firm that ever was.

Adam Feuerstein writes regularly for TheStreet.com. In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet.com. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.
3 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,164.95 -251.90 -1.45%
S&P 500 1,994.99 -26.26 -1.30%
NASDAQ 4,635.24 -48.1670 -1.03%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs